REMARKS

I. Claim Status

Claims 1-30 remain in the application.

II. Rejection Under 35 U.S.C. § 112

Claims 1-30 stand rejected under 35 U.S.C. §112, first paragraph, as allegedly not providing an enablement for making the compounds recited in the claims. Applicants respectfully draw the Examiner's attention to page 30, lines 18-21 of the specification wherein reference to International Application WO 2001/32624 is made. This International Application teaches how to make the compounds recited in the claims. Accordingly, Applicants respectfully request reconsideration and withdrawal of the rejection under 35 U.S.C. §112.

III. Conclusion

In view of the amendments and remarks made above, Applicants believe that this application is now in condition for allowance. Reconsideration and allowance of claims 1-30 is respectfully requested.

The Commissioner is authorized to charge any fee or credit any over payment in connection with this communication to our Deposit Account No. 23-0455.

Date: 4\28\65

Respectfully submitted,

y: Devid D. Kunland

David R. Kurlandsky Registration No. 41,505

Pfizer Inc.

2800 Plymouth Road Ann Arbor, MI 48105

Tel.: (734) 622-7304 Fax: (734) 622-2928